India: Finding Escape Routes: Can Your Invention Avoid Or Overcome Section 3 (i ) Of Indian Patents Act : "Method Of Treatment"

Last Updated: 18 April 2017
Article by Preeti Tyagi

Most of the inventions relating to medical device or an implant face the litmus test –"method of treatment" objection during prosecution by Indian Patent Office. More specifically, if the invention is claiming a method which directly or indirectly makes a reference to a medical condition, it becomes difficult to convince the Examiner. However, there are some successful strategies which can be adopted to avoid such situation or to handle the situation in a better way.

Section 3 defines what not inventions within the meaning of the act are and sub section (i) reads as follows:

Section 3(i): "any process for the medicinal surgical curative, prophylactic diagnostic, therapeutic or other treatment of human beings or any process for a similar treatment of animals to render them free of disease or to increase their economic value or that of their products."

Strategy to handle objection under section 3 (i):-

How to claim method in inventions relating to medical device:-

  1. In the method claims, the terms such as "diagnose an individual", "obtaining test sample from the individual" and " indication that the individual is susceptible to a disease" should be avoided.
  2. Rewording the claim language, for example, in patent application 870/MUM/2007 to receive favourable Controller's decision (Feb 28, 2017), the term "performing" was deleted, a "means for surveying" was replaced by "a surveying coherence optical tomography system for surveying", "means for monitoring and controlling" was replaced by "a surveying controller and an ablating controller acting in a feedback loop for monitoring and controlling". This case has been granted Indian Patent 280777.
  3. Specifying the process to be "in-vitro‟ in claim of the invention. To overcome objection under sections 3(i) in patent application 861/CHE/2007 which was involving isolation of MSCs by negative selection using specific antibody combination viz. Gly-A and CD31, claims have been amended to specify the process to be "in-vitro‟. Specification has been amended to indicate that no embryo or fetus was used or destroyed in the instant application" to overcome objection under section 3(b) - relating to "unethical" invention. Controller's favourable decision came on Feb 6, 2017. This case has been granted Indian Patent 279948.
  4. Method claims in a digital Medical imaging device - Indian Patent 280533 is relating to a system for providing interactive computer aided detection of abnormalities captured in medical images. When the Controller cannot be convinced by Agent's arguments to overcome objection under section 3 (i) on method claims, the agent has made method claim dependent on system claim as " a method of acquiring a medical image, carried out without medication aided by system of claim 1".
  5. Another good example is patent application 5458/DELNP/2006 which is granted as Indian Patent 279332 on January 27, 2017. The examiner has objected to system and method claim relating to sustain release of therapeutically effective amount of the steroid dispersed within biodegradable polymer matrix which is placed in an ocular site or region of an eye under section 3(i). However, the applicant argued that problem to be solved can be seen in the provision of a steroid intraocular implant, having a sustain release of a therapeutically effective amount of steroid from the implant for a time greater than two months. The method claim was presented as "method of making biodegradable intra-ocular implant, comprising the steps of extruding a mixture of steroid & biodegradable polymer to form a biodegradable material that releases drug at a rate effective to sustain release of therapeutically effective amount of the steroid dispersed within biodegradable polymer matrix which is placed in an ocular site or region of an eye".
  6. In the inventions relating to genetic material in a medical device and method, it is advisable that applicant amend claims to recite only the variant form of the known natural sequences, having new substitutions (less than 100 % identity with existing data). BLAST search result for the claimed sequences can be submitted to demonstrate that the claimed sequences are a variant form of the known natural sequences having new substitutions. Claimed specific fragments can be identified by their respective SEQ ID No. Also, source of each of the claimed sequences provided in specification. Accession number of the wild type sequence as well as claimed sequence SEQ ID can be provided. These steps help in convincing the examiner during prosecution of the application.
  7. Directing the invention and method purely for cosmetic purposes. It has been given in recent draft Manual of Patent Practice and Procedure that "application of substances to the body for purely cosmetic purposes is not therapy".

Facing rejection:-

An interesting example is 3321/DELNP/2007 - relating to method for determining if an pancreas isolated from a member of species will be a source of therapeutically useful islets which has been objected under section 3 (i).

In this application, it has been argued that the claimed process does not involve isolation of pancreas and method is carried out on sample, which is isolated pancreas include ischemia time which is defined as the time between initiation of exsanguinations and placement of the pancreas in cold preservative. However, the Controller objected that claims fall within the scope of such clause of section 3(i) of the Patents Act, 1970 as the treatment given to animal during isolation of organ affect the quality of organ as potential donor of islets, such method of treatment of animal increasing the economic value of its organ as donor are not allowable. Further, the Controller has objected that claims fall within the scope of such clause of section 3(b) of the Patents Act, 1970 (relating to morality/ ethical) because pancreas organ has been collected from animal, which were stunned electrically and sample is collected in a manner that Cold ischemia times ranged from 15-20 minutes. Treatment of animal such as electrocution of animals cause very hardship to animal and cause serious prejudice to life to animal and further it is related to trade/commerce in the field of organ trade, and it is against morality. In addition, the Controller has objected that claims fall within the scope of such clause of section 3(k) of the Patents Act, 1970 (relating to Computer/ algorithm) as it is related to evaluation of pancreas biopsies for its suitability for islet isolation by assessing five variables and in each case a score of either +1 or -1 has been assigned to the variable. If more than 15 minutes transpire, a score of -1 was assessed. Thus, present invention is related to scoring method for determining the yield of islets in the isolated pancreas which is a mathematical method, a kind of algorithm for assessing five variables as numerical value has been given as score for phenotypic expression of characteristic of Pancreas biopsies, hence not allowable. This application was rejected under section 3(i), 3(b) and 3(k) of Indian Patents Act.

Most referred decision of the Board of Appeal of the European Patent Office

  1. G 1104 (OJ 2006 334}, has been mostly referred by the agents during prosecution. In G 0001/04 it was stated that an important contribution to diagnoses performed by physicians in private practice and in hospitals was the determination of medical laboratory parameters. Most of these parameters were concentrations of molecules or cells in a body liquid (e.g. blood or urine) and normally determined invitro. The sample (e.g. body fluid) was mixed with the reagents in a reaction vessel, and the detectable change was evaluated by the instrument which belonged to the system. Inventions relating to such in-vitro determination of medical laboratory parameters could in most cases be protected by product claims. But where method claims were appropriate, such methods should neither be excluded from patentability under Article 52(4} EPC, since none of the method steps was carried out on the body. Only if direct interaction with the body made a real difference whether the object of the invention was achieved, should a diagnostic method be regarded as falling within the exclusion under Article 52(4) EPC. Moreover, for the exclusion to operate, the entirety of the diagnostic method had to be practiced on the body. Thus, it is clearly established by the European Patent Office that diagnostic treatment methods performed on the human body are excluded from patentability, however in-vitro assay methods or in-vitro diagnostic methods that is performed on tissue or fluids permanently removed from the body are not excluded from patentability.

    Comparing Article 52(4) EPC provision and Section 3(i) of Indian Patents Act.

    In most of the cases, Indian examiners are allowing method claims where "in-vitro" is specified.

    However, there is no clear distinction of in-vitro or in-vivo diagnostic method in the clause (i) of section 3 of Patents Act, 1970. It is very clearly expressed in the EPC provision on the method practiced on the body of human or animal are only not patentable whereas the provision of clause (i) of section 3 of Patents Act, 1970 states that "any process for the .....diagnostic of human beings...." is not patentable. Therefore, it is strongly advised that along with method claims, system or device claim should be present in patent application. In some cases, technical features of "deleted matter of method claims" have been incorporated as dependent claims on a system.
  2. Decision of Technical Board of Appeal in T383/03 in Europe, in General Hospital Corporation also relied upon by Virulite where the invention related to a method of hair removal from skin region by applying short bursts of light of a selected wavelength to the skin.

    The Board at paragraph 4.1 has held the following:-

    "While the underlying cause of excess hair may be malignancy or endocrinologic diseases, excess hair itself is not harmful and its removal does not treat the underlying cause of unwanted hair, nor is it relevant to the physical health of the treated person, the treatment merely results in an aesthetic improvement of the appearance of the person. The claims are directed to a "cosmetic method" in order to emphasise that the purpose of the claimed method is to improve the aesthetic appearance of the person treated rather than to cure the underlying malady."

    In Virulite, the following two steps were laid down for determining whether a method is a method of treatment or not:-

    1. Whether there is non-insignificant intentional physical intervention
    2. Whether the treatment is suitable or potentially suitable for maintaining or restoring health, the physical integrity, or the physical well being of human beings or animals
    If the response to both the questions is in the affirmative, said method is method of treatment. However, if even one of response is in negative, said method falls outside the exclusion.

Position at Indian Patent Office:

It has been given in recent draft Manual of Indian Patent Practice and Procedure that application of substances to the body for purely cosmetic purposes is not therapy. Therefore, such claims do not fall under section 3(i) of Indian Patents Act.

Conclusion: Inventions relating to medical device or an implant and claiming a method also can avoid objection under section 3 (i) –"method of treatment" during prosecution at Indian Patent Office. There are some successful strategies which can be adopted to avoid such situation or to handle the situation in a better way.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Preeti Tyagi
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Emails

From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.